WO2001022947A2 - Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same - Google Patents
Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same Download PDFInfo
- Publication number
- WO2001022947A2 WO2001022947A2 PCT/EP2000/009061 EP0009061W WO0122947A2 WO 2001022947 A2 WO2001022947 A2 WO 2001022947A2 EP 0009061 W EP0009061 W EP 0009061W WO 0122947 A2 WO0122947 A2 WO 0122947A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- layer
- active
- preparation
- preparation according
- auxiliary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)
Definitions
- the invention relates to preparations containing active substances and / or auxiliary substances for the time and / or dose-controlled release of these substances, the preparations containing at least two layers in rolled or folded form.
- Preparations of any dosage form containing active substance generally release their active substance by diffusion or disintegration, which generally results in non-linear release kinetics.
- Embodiments of such systems can be applied as oral, rectal or vaginal dosage forms, if necessary also as implants.
- a frequent requirement for the form of application is the linear release of active ingredient from the preparation.
- Preparations for such controlled or controlled, for example linear, drug deliveries are usually complicated in structure and expensive to manufacture.
- DE 43 41 442 describes an oral dosage form which consists of a central, active substance-containing, non-erodible layer and a further, largely active substance-free, erodible layer encasing this layer. stands.
- the active ingredient is released by passive diffusion from the central layer, which is exposed to the release medium with a defined area.
- the reduction in the amount of active ingredient released by diffusion per unit of time is compensated for by the additional active ingredient released from the jacket layer due to erosion of core areas.
- No. 3,625,214 describes a sheet-like, spirally rolled-up dosage form which comprises two layers, the outwardly facing layer being a water-soluble but impermeable, active substance-free film which is coated with an inwardly wound, water-soluble and active substance-containing matrix, the latter Matrix can have a thickness profile along its extent.
- the invention for the controlled release of active substance comprises spirally rolled or folded layers on a polymer film which contains a pharmaceutical active substance.
- the invention is characterized in that the outer surface of the active substance-containing polymer film, accessible to the digestive juices, in the rolled-up or folded state is at most 25% of its total surface and the rolled-up or folded layers adhere to one another in such a way that the laminar pharmaceutical form in the release test according to USP 23, method A, apparatus 2, at 37 C and 50 rpm in artificial gastric juice maintains its spirally rolled or folded shape for at least one hour and at least 30% of the active ingredient contained is released in the rolled or folded state.
- No. 4,767,627 describes an active ingredient-providing preparation with an extended residence time in the stomach, which comprises a planar configuration of an erodable polymer which releases an active ingredient contained therein over a controlled, predeterminable and extended period of time.
- US 4,268,497 describes a preparation for oral administration in veterinary medicine which contains a medicament in an erodible film.
- the film has a first shape that allows oral administration and a second shape in the stomach that retains it.
- the invention has for its object to provide an application form for a preparation containing an active ingredient, which is less complicated to manufacture and allows a freely modulatable release with simple and inexpensive means.
- a preparation which has the features mentioned in the preamble of the main claim contains at least one active ingredient or auxiliary in the first layer, and that this layer is continuous at least in sections, and that at least one of the parameters is thickness , Width and concentration of the active or auxiliary substance of this layer is not constant.
- the preparations according to the invention are characterized in that the second layer is continuous and has a lower moisture permeability than the first layer.
- the invention relates to a preparation containing active substances and / or auxiliary substances with the features mentioned, for the time and / or dose-controlled release of these substances, this preparation containing at least two layers (1, 2) in rolled or folded form.
- the entire length of the carrier layer (1) can be covered by an active substance-containing matrix layer (2), but it can also have active substance-free regions in the longitudinal direction, so that active substance-containing and active substance-free regions alternate at intervals.
- the carrier layer in its longitudinal direction can also have regions with matrix layers which contain different active substances and / or auxiliary substances.
- Embodiments which have at least one continuous and essentially moisture-impermeable layer are particularly advantageous. If this appears advantageous, this layer can also contain active ingredients or auxiliaries, or both together.
- Another embodiment provides that at least one of the layers (2) of the laminate is soluble or erodible in body fluid, and another layer (1) is less readily soluble or harder to erode, or even insoluble or not erodible.
- solubility or degradability there is an interrelation between solubility or degradability on the one hand and the thickness of the material on the other.
- a largely insoluble material can be made relatively thin, while on the other hand, when using moisture-permeable, more easily soluble, erodible or biodegradable materials, the layers must be correspondingly thicker.
- the concentration of active substance is usually the same everywhere over the length of the layer containing the active substance. However, it can be advantageous if, according to a preferred embodiment of the invention, the concentration of the active ingredient or active ingredients is different in relation to the longitudinal extent of the active ingredient-containing layer (s).
- the concentration differences can preferably be in the form of a concentration gradient. be designed, or in the form of a differently variable concentration profile.
- At least one layer is pressure-sensitive adhesive.
- the active substance layer also referred to as a matrix, can have a uniform thickness over its entire length, in which case the width of this layer can vary over the extent in the longitudinal direction. This results in the so-called latitude profile.
- the outer layer in the case of a rolled-up laminate, can contain active ingredients and / or auxiliary substances.
- a pressure-sensitive adhesive, liquid-soluble active substance layer can be provided on the inside of the winding, so that the largely active substance-free carrier layer thereby prevents premature release of the active substance. If this preparation, which is rolled up in a spiral, is exposed to a body fluid, the adhesive containing the active ingredient dissolves and partially unrolls the system. Depending on the currently exposed area, the active ingredient can then diffuse or dissolve from the layer into the body fluid. The release profile is thus controlled by the geometry of the active substance layer. Slowly unrolling the system gradually reveals new active substance-containing surfaces, so that the release profile results from the layer geometry and unrolling speed.
- the measure can be provided such that the active substance-containing layer is on the outside of the spiral, while the inner winding is formed by the carrier layer.
- the advantage of this embodiment is the initial dose, which is provided by the outer winding containing the active ingredient.
- a further embodiment of the invention provides that layer areas with active substances and / or auxiliary substances are present which differ with regard to their ingredients or their solubility, adhesive power or erosion properties.
- the release profile can thus be further modulated and, in particular, dose-modulated.
- the release of active substance is controlled in "bursts" following in time by exposing different surfaces with different active substances and auxiliary substances.
- the active ingredient layer can be formed by two areas carrying different active ingredients, one of these areas providing a pulsed delivery, while another area enables continuous release of active ingredients.
- the invention further includes the possibility that the sheet-like laminate is wound onto a winding core, which is removed after the winding has ended, so that a central recess is formed.
- This can have a diameter of 0.5 to 30 mm, preferably 1 to 10 mm, particularly preferably 2 to 5 mm.
- the winding core can also remain in the system as a component of the preparation, this winding core being compact or hollow, in the form of a ring, containing an active ingredient or being largely free of active ingredient.
- the width of the wiki core exceed the maximum width of the laminate.
- the diameter of this winding core is 0.5 mm to 30 mm, preferably 1 to 10 mm and particularly preferably 2 to 5 mm.
- the active ingredient can be released by diffusion and / or dissolution of the active ingredient from an active ingredient layer largely insoluble in an acidic and / or basic environment, or by disintegration or dissolution of an active ingredient layer soluble in an acidic and / or basic environment.
- Layer is in the range between 1 ⁇ m and 500 ⁇ m, preferably between 5 ⁇ m and 150 ⁇ m, particularly preferably between
- the width of an active substance-containing layer can be in the range between 1 mm and 50 mm, preferably between 1 mm and 30 mm, particularly preferably between 10 mm and 30 mm.
- the area of the active substance layer, based on the carrier layer is in the range between 1 and 99%, preferably between 10 and 80%, particularly preferably between 30 and 70%.
- the unwound length of the overall system can advantageously be in the range between 5 mm and 300 mm, preferably between 10 mm and 200 mm, particularly preferably between 10 mm and 50 mm.
- embodiments of the invention which are characterized by a linear release course are particularly preferred. Furthermore, embodiments are particularly preferred which have the ability to release an initial dose.
- the initial dose can be provided, for example, by an outer winding containing the active ingredient.
- the rolled or folded preparations according to the invention are provided with additional covering layers on the sides which correspond to the long sides of the respective layers. This creates protection against the attack of water or body fluids.
- These side cover layers preferably contain essentially moisture-impermeable materials.
- the rolled up or folded preparations according to the invention are preferably embedded in a substrate which can consist of a substance which is soluble in an acidic or basic medium, for example in the form of hard or soft gelatin capsules.
- a use of the preparation according to the invention is provided for the controllable release of active substance in the gastric juice area.
- it can also be provided for the controllable release of active substance in the gastrointestinal tract, in particular in the small intestine.
- the preparation is preferably used for any modulable control and in particular for linear control of the release of active ingredient.
- the release of active ingredient can also be provided in the large intestine.
- the preparation for the controllable release of active ingredient and auxiliary for example in the form of a molded product such as a suppository, in the anal or vaginal area, or as an implant.
- Suitable active substances can be found in the active substance groups of parasy patholytics (for example scopolamine, atropine, berlactyzine), cholinergics (eg physostigmine, nicotin), neuroleptics (eg chlorpromazine, haloperidol), monoamine oxidase inhibitors (eg tranylcypromine, Selegi - lin), the sympathomimetics (e.g. ephedrine, D-norpseudo-ephedrine, salbutamol, fenfluramine), the sympatholytics and antisympathotonics (e.g.
- parasy patholytics for example scopolamine, atropine, berlactyzine
- cholinergics eg physostigmine, nicotin
- neuroleptics eg chlorpromazine, haloperidol
- indomethacin piroxicam, lornoxicam
- coronary drugs eg glycerol trinitrate, isosorbide dinitrate
- the estrogenic, progestogen and androgen eg diphenhydramine, clastin, terfenadine
- the prostaglandin derivatives eg diphenhydramine, clastin, terfenadine
- the vitamins eg vitamin E, Cholecalciferol
- the cytostatics un d cardiac glycosides such as digitoxin and digoxin.
- Polymers such as polyisobutylene, esters of polyvinyl alcohol, polyacrylic, polymethacrylic and polymethyl methacrylic acid and their derivatives, natural rubber, styrene, isoprene and styrene-butadiene polymers or silicone polymers, resin components such as saturated and unsaturated hydrocarbon resins can be used as constituents in the base material of the layers containing the active ingredient.
- resin components such as saturated and unsaturated hydrocarbon resins can be used as constituents in the base material of the layers containing the active ingredient.
- plasticizers such as phthalic esters, triglycerides and fatty acids, and a number of other substances known to the person skilled in the art are used.
- polyvinyl alcohol polyvinyl alcohol
- styrene / diene block copolymers polyurethanes
- polyvinyl chloride poly methacrylates
- polyacrylate polymethylacrylate
- polyethyl methacrylate and derivatives polyolefins and polyester to name just a few examples.
- a method for producing a preparation according to the invention is characterized by the working steps listed in claim 20.
- One embodiment of the method provides that parts of the active and / or auxiliary layer in the longitudinal extension of the laminate are removed or additionally added to achieve a desired release program after application. Additional active layers can also be laminated onto the laminate. Finally, a last step of the method provides that the preparation is embedded in a substrate.
- Figures I a / b, Figures II a-g, Figures III and IV, Figures V a / b and Figures VI a / b each show a side view or a top view of preparations according to the invention in a substrate containing these preparations.
- FIG. Ia shows a pressure-sensitive adhesive, water-soluble active substance layer (2) on the inside of the winding, the active substance-free carrier layer (1) preventing early release of the active substance. If this rolled-up preparation set, the active ingredient-containing adhesive loosens and partially unrolls the system. In this case, according to the respectively exposed area, active ingredient can pass into the body fluid by diffusion or solution from the layer (2).
- the release profile is thus controlled by the geometry of the active substance layer, new surfaces containing the active substance being successively exposed by slowly unrolling the system and the release profile resulting from the layer geometry and unrolling speed.
- the active substance-containing layer (2) is on the outside of the spiral, while the inner winding is formed by the carrier layer.
- the advantage of this embodiment is the initial dose, which is provided by the outer winding containing the active substance.
- Figures II a, d, f, g each show different embodiments of the partially unrolled system in plan view, while Figures II d, c, e show the embodiments in side view.
- FIGS. II a, b enables a pulsed delivery of the active substance, while the embodiments II d, e result in a modulated swelling or swelling of the delivery.
- Fig. II f relates to a variant which provides a slow inflow or outflow of the active ingredient.
- Fig. II g shows another embodiment in which a constant release of active ingredient is provided, as is known in the pharmaceutical industry as zero order release.
- FIG. III shows an embodiment of this type, the active ingredient layer being separated by two different areas carrying the active ingredients (FIGS. III, 2, 3). is formed and in this case area 2 provides a pulsed delivery, while area 3 enables a continuous release of active ingredient.
- the embodiment in FIG. IV likewise comprises two areas: area 2 is designed as an active ingredient-containing, water-soluble adhesive, area 3, on the other hand, as a largely active ingredient-free or active ingredient-containing but water-insoluble sealing area.
- area 2 is designed as an active ingredient-containing, water-soluble adhesive
- area 3 on the other hand, as a largely active ingredient-free or active ingredient-containing but water-insoluble sealing area.
- the water-insoluble sealing area at the edges takes on a protective function, because without this barrier, active substance would be released early via the sides when rolled out.
- the stability of the rolled-up preparation is generated by the centrally applied adhesive in area 2 and only insignificantly by the barrier area. This ensures that the active ingredient is only released via the unrolled, uncovered surfaces.
- the end faces of a rolled-up system are slowly glued or sealed.
- Fig. V a, e shows an example of this embodiment.
- This layer can be made of active substance or free of active substance, soluble or insoluble in water.
- VI a, b shows a top and side view of the preparation according to the invention in a substrate 5 containing this preparation, which consists of a substance which is soluble in an acidic and / or basic medium.
- a substrate 5 containing this preparation which consists of a substance which is soluble in an acidic and / or basic medium.
- the carrier layer can be eroded or in water is soluble.
- the pressure-sensitive adhesive layer can be insoluble.
- Figure VI shows the preparation according to the invention einsde substrate 5 in plan view (VI a) or in S eitenansicht (VI b).
- the preparation may be as rigid Bezie h ung Spotify soft gelatin capsule to be carried out, but they can also be in the form of suppositories.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0014647-1A BR0014647A (en) | 1999-09-30 | 2000-09-16 | Preparation containing active substance (s) and / or auxiliary (s) for the release of time and / or controllable dose of said substances, use of the preparation and process for the preparation of the preparation |
AU75196/00A AU777621B2 (en) | 1999-09-30 | 2000-09-16 | Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
IL148907A IL148907A (en) | 1999-09-30 | 2000-09-16 | Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
DE50012202T DE50012202D1 (en) | 1999-09-30 | 2000-09-16 | ACTIVE AND / OR AUXILIARY PREPARATIONS WITH CONTROLLABLE RELEASE OF SUCH SUBSTANCES, AND THEIR USE AND MANUFACTURE |
MXPA02003252A MXPA02003252A (en) | 1999-09-30 | 2000-09-16 | Preparation containing active ingredients and or auxiliary agents with a controlled release of these substances and the use and production of the same. |
CA2387710A CA2387710C (en) | 1999-09-30 | 2000-09-16 | Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
EP00964184A EP1216035B1 (en) | 1999-09-30 | 2000-09-16 | Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
JP2001526159A JP2003510270A (en) | 1999-09-30 | 2000-09-16 | Formulations containing active and / or auxiliary substances and providing controlled release of said substances, and their use and manufacture |
CY20061100597T CY1106080T1 (en) | 1999-09-30 | 2006-05-08 | PREPARATION CONTAINING ACTIVE AND/OR AUXILIARY SUBSTANCES, WITH DIRECTED RELEASE OF THESE SUBSTANCES, AS WELL AS ITS USE AND PREPARATION |
US12/031,570 US20080241216A1 (en) | 1999-09-30 | 2008-02-14 | Preparation Containing Active and/or Auxiliary Substances, With Controllable Release of Said Substances, As Well As Its Use and Manufacture |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19946822.2 | 1999-09-30 | ||
DE19946822A DE19946822A1 (en) | 1999-09-30 | 1999-09-30 | Preparation containing active and / or auxiliary substances with controllable release of these substances, as well as their use and production |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001022947A2 true WO2001022947A2 (en) | 2001-04-05 |
WO2001022947A3 WO2001022947A3 (en) | 2001-10-11 |
Family
ID=7923805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/009061 WO2001022947A2 (en) | 1999-09-30 | 2000-09-16 | Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080241216A1 (en) |
EP (1) | EP1216035B1 (en) |
JP (1) | JP2003510270A (en) |
KR (1) | KR100666901B1 (en) |
CN (1) | CN1232245C (en) |
AR (1) | AR025914A1 (en) |
AT (1) | ATE317258T1 (en) |
AU (1) | AU777621B2 (en) |
BR (1) | BR0014647A (en) |
CA (1) | CA2387710C (en) |
CY (1) | CY1106080T1 (en) |
DE (2) | DE19946822A1 (en) |
DK (1) | DK1216035T3 (en) |
ES (1) | ES2258019T3 (en) |
IL (1) | IL148907A (en) |
MX (1) | MXPA02003252A (en) |
PT (1) | PT1216035E (en) |
TW (1) | TWI255724B (en) |
WO (1) | WO2001022947A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2839645A1 (en) * | 2002-05-15 | 2003-11-21 | Backert Marie Elisabeth Cuine | Multilayer system for oral administration of drug(s), especially with specific release profile, comprises polymeric film carrier coated by spreading with drug-containing matrix layer(s) |
EP1920768A1 (en) * | 2006-11-10 | 2008-05-14 | Abbott GmbH & Co. KG | Solid dosage form with a film containing an active substance, as well as its method of production |
US11419824B2 (en) | 2017-12-29 | 2022-08-23 | Laxxon Medical Ag | Drug delivery system |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9205089B2 (en) | 2011-04-29 | 2015-12-08 | Massachusetts Institute Of Technology | Layer processing for pharmaceuticals |
US10213960B2 (en) | 2014-05-20 | 2019-02-26 | Massachusetts Institute Of Technology | Plasticity induced bonding |
US9808608B2 (en) | 2014-11-16 | 2017-11-07 | International Business Machines Corporation | Helical coil delivery device for active agent |
WO2019129361A1 (en) * | 2017-12-29 | 2019-07-04 | Laxxon Medical Ag | Method for producing a drug delivery system |
DE102021106491A1 (en) | 2021-03-17 | 2022-09-22 | Lts Lohmann Therapie-Systeme Ag. | ROLLED ORAL THIN FILM WITH HIGH LOADING OF ACTIVE INGREDIENTS |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
DE2656387A1 (en) * | 1975-12-15 | 1977-06-30 | Hoffmann La Roche | SOLID UNIVERSAL PHARMACEUTICAL DOSAGE FORM AS A DOSAGE FORM OF A DRUG, AND PROCESS AND SYSTEM FOR THEIR MANUFACTURING |
EP0010987A1 (en) * | 1978-11-07 | 1980-05-14 | Beecham Group Plc | Device for oral administration to a ruminant animal |
EP0872234A2 (en) * | 1997-04-16 | 1998-10-21 | Röhm Gmbh | Laminar medical formulation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US4601893A (en) * | 1984-02-08 | 1986-07-22 | Pfizer Inc. | Laminate device for controlled and prolonged release of substances to an ambient environment and method of use |
US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US5700478A (en) * | 1993-08-19 | 1997-12-23 | Cygnus, Inc. | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
-
1999
- 1999-09-30 DE DE19946822A patent/DE19946822A1/en not_active Withdrawn
-
2000
- 2000-09-16 AU AU75196/00A patent/AU777621B2/en not_active Ceased
- 2000-09-16 BR BR0014647-1A patent/BR0014647A/en active Search and Examination
- 2000-09-16 AT AT00964184T patent/ATE317258T1/en active
- 2000-09-16 ES ES00964184T patent/ES2258019T3/en not_active Expired - Lifetime
- 2000-09-16 DK DK00964184T patent/DK1216035T3/en active
- 2000-09-16 EP EP00964184A patent/EP1216035B1/en not_active Expired - Lifetime
- 2000-09-16 WO PCT/EP2000/009061 patent/WO2001022947A2/en active IP Right Grant
- 2000-09-16 DE DE50012202T patent/DE50012202D1/en not_active Expired - Lifetime
- 2000-09-16 CN CNB008135320A patent/CN1232245C/en not_active Expired - Fee Related
- 2000-09-16 CA CA2387710A patent/CA2387710C/en not_active Expired - Fee Related
- 2000-09-16 KR KR1020027004115A patent/KR100666901B1/en not_active IP Right Cessation
- 2000-09-16 IL IL148907A patent/IL148907A/en not_active IP Right Cessation
- 2000-09-16 PT PT00964184T patent/PT1216035E/en unknown
- 2000-09-16 MX MXPA02003252A patent/MXPA02003252A/en active IP Right Grant
- 2000-09-16 JP JP2001526159A patent/JP2003510270A/en active Pending
- 2000-09-28 TW TW089120055A patent/TWI255724B/en not_active IP Right Cessation
- 2000-09-29 AR ARP000105150A patent/AR025914A1/en unknown
-
2006
- 2006-05-08 CY CY20061100597T patent/CY1106080T1/en unknown
-
2008
- 2008-02-14 US US12/031,570 patent/US20080241216A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
DE2656387A1 (en) * | 1975-12-15 | 1977-06-30 | Hoffmann La Roche | SOLID UNIVERSAL PHARMACEUTICAL DOSAGE FORM AS A DOSAGE FORM OF A DRUG, AND PROCESS AND SYSTEM FOR THEIR MANUFACTURING |
EP0010987A1 (en) * | 1978-11-07 | 1980-05-14 | Beecham Group Plc | Device for oral administration to a ruminant animal |
EP0872234A2 (en) * | 1997-04-16 | 1998-10-21 | Röhm Gmbh | Laminar medical formulation |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2839645A1 (en) * | 2002-05-15 | 2003-11-21 | Backert Marie Elisabeth Cuine | Multilayer system for oral administration of drug(s), especially with specific release profile, comprises polymeric film carrier coated by spreading with drug-containing matrix layer(s) |
WO2003097019A1 (en) * | 2002-05-15 | 2003-11-27 | Marie Elisabeth Cuine-Backert | Multilamellar system for the administration of active agents by means of ingestion |
EP1920768A1 (en) * | 2006-11-10 | 2008-05-14 | Abbott GmbH & Co. KG | Solid dosage form with a film containing an active substance, as well as its method of production |
WO2008056001A1 (en) * | 2006-11-10 | 2008-05-15 | Abbott Gmbh & Co. Kg | Solid dosage form with a film containing an active substance, as well as its method of production |
US8673344B2 (en) | 2006-11-10 | 2014-03-18 | AbbVie Deutschland GmbH & Co. KG | Solid dosage form with a film containing an active substance, as well as its method of production |
US11419824B2 (en) | 2017-12-29 | 2022-08-23 | Laxxon Medical Ag | Drug delivery system |
Also Published As
Publication number | Publication date |
---|---|
AU777621B2 (en) | 2004-10-21 |
JP2003510270A (en) | 2003-03-18 |
CA2387710C (en) | 2010-02-23 |
IL148907A (en) | 2008-11-26 |
TWI255724B (en) | 2006-06-01 |
WO2001022947A3 (en) | 2001-10-11 |
EP1216035A2 (en) | 2002-06-26 |
MXPA02003252A (en) | 2003-04-10 |
DK1216035T3 (en) | 2006-06-12 |
CA2387710A1 (en) | 2001-04-05 |
CN1377258A (en) | 2002-10-30 |
EP1216035B1 (en) | 2006-02-08 |
US20080241216A1 (en) | 2008-10-02 |
CN1232245C (en) | 2005-12-21 |
KR20020038784A (en) | 2002-05-23 |
ATE317258T1 (en) | 2006-02-15 |
PT1216035E (en) | 2006-06-30 |
DE19946822A1 (en) | 2001-04-26 |
BR0014647A (en) | 2002-11-19 |
AU7519600A (en) | 2001-04-30 |
AR025914A1 (en) | 2002-12-18 |
ES2258019T3 (en) | 2006-08-16 |
IL148907A0 (en) | 2002-09-12 |
KR100666901B1 (en) | 2007-01-11 |
DE50012202D1 (en) | 2006-04-20 |
CY1106080T1 (en) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3910543C2 (en) | ||
EP0889723B1 (en) | Transdermal therapeutic system with small application-area thickness and great flexibility, and production process | |
EP0872234B1 (en) | Laminar medical formulation | |
EP0659075B1 (en) | Process for producing a flat active substance administration form | |
WO1988001516A1 (en) | Transdermal therapeutic system, its use and production process | |
US20080241216A1 (en) | Preparation Containing Active and/or Auxiliary Substances, With Controllable Release of Said Substances, As Well As Its Use and Manufacture | |
DE10252726B4 (en) | Multilayer transmucosal therapeutic system | |
DE2419795C2 (en) | Shaped body for delivering an active ingredient to an aqueous environment | |
EP1971328B1 (en) | Transdermal therapeutic system for volatile and/or thermolabile substances | |
DE2328409C3 (en) | Active substance dispenser working according to the osmosis principle | |
WO2000010539A1 (en) | Active ingredient support in the form of a film | |
DE19708674C2 (en) | Transdermal therapeutic system with a drug-containing film layer and a soluble release layer, and a method for its preparation | |
DE19956486A1 (en) | Multi-layer preparation for the controlled, pulsed delivery of active ingredients | |
EP1087759B1 (en) | Method for manufacturing a laminate consisting of individual layers | |
DE3823070A1 (en) | Self-adhesive plaster | |
DE3843237A1 (en) | TRANSDERMAL THERAPEUTIC SYSTEM WITH AN ANTIADIPOSITUM AS AN ACTIVE INGREDIENT | |
WO2000025759A1 (en) | Orally applicable therapeutic dosage form which spontaneously disintegrates upon contact with a liquid and method for producing the same | |
WO1999058107A2 (en) | Oral or mucosal preparation containing an active ingredient, with controlled active ingredient release, and its use | |
EP1079815B1 (en) | Timed-release transdermal systems containing an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000964184 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/00323/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 148907 Country of ref document: IL Ref document number: 75196/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/003252 Country of ref document: MX Ref document number: 2387710 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008135320 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2001 526159 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027004115 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002108570 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10089444 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027004115 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000964184 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 75196/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000964184 Country of ref document: EP |